Last Week Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Ratings

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Ratings Coverage

In total 2 analysts cover Eagle Pharmaceuticals (NASDAQ:EGRX). “Buy” rating has 1, “Sell” are 0, while 1 are “Hold”. 50% are bullish. 2 are the (NASDAQ:EGRX)’s analyst reports since September 21, 2018 according to StockzIntelligence Inc. The stock rating was downgraded by PiperJaffray to “Neutral” on Wednesday, October 31. On Friday, September 21 the rating was maintained by Cantor Fitzgerald with “Overweight”. Listed here are Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) PTs and latest ratings.

31/10/2018 Broker: PiperJaffray Old Rating: Overweight New Rating: Neutral Old Target: $82 New Target: $54 Downgrade
21/09/2018 Broker: Cantor Fitzgerald Old Rating: Overweight New Rating: Overweight Old Target: $81 New Target: $80 Maintain

EGRX is hitting $39.53 during the last trading session, after increased 0.48%.Eagle Pharmaceuticals, Inc. has volume of 188,205 shares. Since February 14, 2018 EGRX has declined 22.74% and is downtrending. The stock underperformed the S&P500 by 22.74%.

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States.The firm is valued at $589.52 million. The firm offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.The P/E ratio is 21.54. The Company’s product candidates includes include EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer.

For more Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) news announced briefly go to: Businesswire.com, Businesswire.com, Businesswire.com, Businesswire.com or Seekingalpha.com. The titles are as follows: “Eagle Pharmaceuticals, Inc. Granted Final FDA Approval for Bendamustine Hydrochloride Ready-to-Dilute Solution in a 500ml Admixture – Business Wire” announced on May 16, 2018, “Eagle Pharmaceuticals Named to Fortune 100 List of Fastest-Growing Companies – Business Wire” on August 23, 2018, “Court Issues Decision in Favor of Eagle Pharmaceuticals Granting Seven Year Orphan Drug Exclusivity for BENDEKA (bendamustine hydrochloride injection) – Business Wire” with a publish date: June 11, 2018, “Eagle Pharmaceuticals, Inc. to Present at Investor Conferences in June – Business Wire” and the last “Eagle Pharma OKs $150M in stock buybacks – Seeking Alpha” with publication date: October 30, 2018.

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.